Table 3 Mean TK parameters and accumulation ratio of HX009 injection groups after the first and last dosing (Mean ± SD).
From: Preclinical pharmacology characterization of HX009, a novel PD1 x CD47 Bi-specific antibody
Dose level | Sex | Day1 | Day29 | AR | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Tmax | Cmax | AUClast | N | Tmax | Cmax | AUClast | N | Cmax | AUClast | N | ||
(h) | (µg/mL) | (h*µg/mL) | (h) | (µg/mL) | (h*µg/mL) | |||||||
3 mg/kg | M | 1.213 ± 1.631 | 56.22 ± 4.83 | 3214.10 ± 360.51 | 5 | 0.033 ± 0.000 | 14.15 ± 7.76 | 34.90 ± 22.76 | 3 | 0.24 ± 0.11 | 0.01 ± 0.01 | 3 |
F | 0.420 ± 0.530 | 51.65 ± 10.98 | 2771.49 ± 745.73 | 5 | 0.033 ± 0.000 | 15.31 ± 3.84 | 46.99 ± 23.92 | 3 | 0.35 ± 0.16 | 0.02 ± 0.02 | 3 | |
F + M | 0.817 ± 1.217 | 53.93 ± 8.35 | 2992.80 ± 599.45 | 10 | 0.033 ± 0.000 | 14.73 ± 5.51 | 40.95 ± 21.91 | 6 | 0.30 ± 0.14 | 0.02 ± 0.01 | 6 | |
15 mg/kg | M | 0.613 ± 0.530 | 348.96 ± 38.48 | 20,537.81 ± 1715.63 | 5 | 0.033 ± 0.000 | 43.54 ± 35.21 | 151.76 ± 173.91 | 5 | 0.13 ± 0.12 | 0.01 ± 0.01 | 5 |
F | 0.613 ± 0.530 | 380.01 ± 50.62 | 23,489.82 ± 5234.36 | 5 | 0.033 ± 0.000 | 117.20 ± 108.21 | 1219.94 ± 2072.25 | 5 | 0.32 ± 0.30 | 0.05 ± 0.08 | 5 | |
F + M | 0.613 ± 0.499 | 364.48 ± 45.44 | 22,013.81 ± 3988.22 | 10 | 0.033 ± 0.000 | 80.37 ± 85.22 | 685.85 ± 1496.31 | 10 | 0.23 ± 0.23 | 0.03 ± 0.06 | 10 | |
50 mg/kg | M | 0.420 ± 0.530 | 1167.70 ± 95.57 | 87,209.34 ± 4415.53 | 5 | 0.275 ± 0.484 | 913.39 ± 564.62 | 27,996.20 ± 37,411.91 | 4 | 0.75 ± 0.45 | 0.32 ± 0.43 | 4 |
F | 0.420 ± 0.530 | 1234.16 ± 134.14 | 84,926.08 ± 8105.55 | 5 | 0.355 ± 0.558 | 1076.35 ± 542.42 | 18,800.29 ± 14,903.19 | 3 | 0.85 ± 0.41 | 0.22 ± 0.19 | 3 | |
F + M | 0.420 ± 0.499 | 1200.93 ± 115.25 | 86,067.71 ± 6270.04 | 10 | 0.309 ± 0.472 | 983.23 ± 514.84 | 24,055.10 ± 28,249.28 | 7 | 0.80 ± 0.40 | 0.27 ± 0.33 | 7 | |
